Author:
Zhao Yangting,Pan Binjing,Lv Xiaoyu,Chen Chongyang,Li Kai,Wang Yawen,Liu Jingfang
Abstract
Diabetic cardiomyopathy (DCM) is a serious complication of type 1 and type 2 diabetes, which leads to the aggravation of myocardial fibrosis, disorders involving systolic and diastolic functions, and increased mortality of patients with diabetes through mechanisms such as glycolipid toxicity, inflammatory response, and oxidative stress. Ferroptosis is a form of iron-dependent regulatory cell death that is attributed to the accumulation of lipid peroxides and an imbalance in redox regulation. Increased production of lipid reactive oxygen species (ROS) during ferroptosis promotes oxidative stress and damages myocardial cells, leading to myocardial systolic and diastolic dysfunction. Overproduction of ROS is an important bridge between ferroptosis and DCM, and ferroptosis inhibitors may provide new targets for the treatment of patients with DCM.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Gansu Province
Subject
Endocrinology, Diabetes and Metabolism
Reference84 articles.
1. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res Clin Pract,2022
2. Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes;Park;Diabetes Metab J,2021
3. Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the thousand & 1 study;Jensen;Diabetologia,2014
4. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome;Kiencke;Eur J Heart Fail,2010
5. Diabetic cardiomyopathy: prevalence, determinants and potential treatments;Gulsin;Ther Adv Endocrinol Metab,2019
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献